Actrapid InnoLet: Uses, Dosage & Side Effects

What Is Actrapid InnoLet and What Is It Used For?

Actrapid InnoLet is a rapid-acting (soluble) human insulin manufactured by Novo Nordisk using recombinant DNA technology. The “InnoLet” refers to the unique pre-filled, disposable pen device that contains 3 ml of insulin solution at a concentration of 100 IU/ml, providing a total of 300 units per pen. Unlike the Actrapid Penfill cartridge that requires a separate reusable pen, the InnoLet is a self-contained, ready-to-use device — patients simply attach a needle and begin injecting without needing additional equipment.

The InnoLet pen was specifically engineered for patients who may find conventional insulin pens difficult to use. Its distinguishing features include an exceptionally large dose dial with clearly printed numbers, an audible clicking sound for each unit dialled, and an ergonomic shape that requires minimal hand strength to operate. These design elements make the InnoLet particularly valuable for elderly patients, individuals with visual impairment, and those with conditions affecting hand dexterity such as arthritis or neuropathy. The pen delivers doses from 1 to 50 units in 1-unit increments.

Diabetes mellitus is a chronic metabolic condition characterised by the body's inability to produce sufficient insulin or to use insulin effectively. In type 1 diabetes, the immune system destroys the insulin-producing beta cells of the pancreas, leading to complete insulin deficiency. These patients require lifelong insulin replacement from the time of diagnosis. In type 2 diabetes, the body becomes resistant to insulin's effects and may eventually lose the ability to produce enough insulin. Many people with advanced type 2 diabetes require insulin therapy when oral medications alone no longer provide adequate blood sugar control.

Actrapid is specifically designed for mealtime (prandial) use. When you eat food containing carbohydrates, your blood sugar rises. Actrapid provides a burst of insulin activity that helps your cells absorb this glucose, preventing dangerous spikes in blood sugar after meals. It begins to lower blood sugar approximately 30 minutes after subcutaneous injection, reaches its peak effect between 1.5 and 3.5 hours, and has a total duration of action of approximately 7 to 8 hours. Because of this 30-minute onset, patients are advised to inject Actrapid approximately half an hour before eating.

Actrapid InnoLet is most commonly prescribed as part of a basal-bolus insulin regimen. In this approach, a longer-acting insulin (such as insulin glargine, insulin detemir, or isophane insulin) provides a steady background level of insulin throughout the day and night, while Actrapid is injected before each main meal to handle the post-meal blood sugar rise. This combination closely mimics the natural pattern of insulin secretion in people without diabetes, providing both continuous baseline coverage and mealtime bursts of insulin activity.

According to the International Diabetes Federation, approximately 537 million adults worldwide live with diabetes, and this number continues to rise. Insulin therapy — including rapid-acting formulations like Actrapid — remains a cornerstone of diabetes management. Human insulin is included on the WHO Model List of Essential Medicines, reflecting its critical importance in global healthcare. Unlike newer insulin analogues, human insulin has the advantage of decades of clinical experience and is generally available at a lower cost, making it an essential option in both high-income and resource-limited settings.

What Should You Know Before Taking Actrapid InnoLet?

Contraindications

You should not use Actrapid InnoLet in the following circumstances:

• Allergy: If you are allergic (hypersensitive) to human insulin or any of the other ingredients in Actrapid (zinc chloride, glycerol, metacresol, sodium hydroxide, hydrochloric acid, or water for injections).
• Hypoglycemia: If you feel the onset of hypoglycemia (low blood sugar symptoms such as sweating, trembling, rapid heartbeat, confusion, or dizziness), do not inject additional insulin.
• Do not refill: The Actrapid InnoLet is a pre-filled disposable pen. It must never be refilled. Once the pen is empty, discard the entire device and start a new pen.
• Damaged product: If the pen device has been dropped, damaged, or crushed, do not use it as the dosing mechanism may be compromised.
• Improper storage: If the insulin has not been stored correctly or has been frozen, it must be discarded.
• Appearance: If the solution is not clear and colorless, do not use it. Actrapid should never appear cloudy or contain particles.

Warnings and Precautions

Before and during treatment with Actrapid InnoLet, discuss the following important considerations with your healthcare provider:

• Kidney, liver, or endocrine problems: If you have impaired kidney or liver function, or conditions affecting the adrenal glands, pituitary gland, or thyroid, your insulin requirements may change significantly. Your doctor may need to adjust your dose and increase the frequency of blood sugar monitoring.
• Physical activity changes: If you exercise more than usual or wish to change your diet significantly, your blood sugar levels can be affected and your insulin dose may need to be adjusted. Increased physical activity generally lowers blood sugar, potentially requiring a reduction in insulin dose or additional carbohydrate intake.
• Illness: If you become unwell with an infection, fever, or other illness, your insulin requirements may increase even if you are eating less. Continue taking your insulin and contact your healthcare provider for guidance on dose adjustments. Never stop insulin therapy without medical supervision.
• Travel: Travelling across time zones can affect your insulin schedule and requirements. Discuss adjustments with your doctor before travelling internationally. Keep insulin in your hand luggage during flights and protect it from extreme temperatures.
• Switching insulin products: If you are switched from another type of insulin or from a different insulin brand, your dose may need to be adjusted. This should always be done under medical supervision, as different insulin formulations can have different onset, peak, and duration profiles.

Pregnancy and Breastfeeding

If you are pregnant, believe you may be pregnant, or are planning to become pregnant, consult your doctor before using Actrapid. Insulin is the preferred treatment for diabetes during pregnancy because it does not cross the placenta in significant amounts and is considered safe for the developing baby. Maintaining careful blood sugar control during pregnancy is critically important to prevent complications for both mother and child, including pre-eclampsia, macrosomia (large baby), birth defects, and neonatal hypoglycemia.

Insulin requirements typically change throughout pregnancy. They may decrease during the first trimester and then increase significantly during the second and third trimesters as insulin resistance increases. After delivery, insulin needs usually drop rapidly and may require prompt adjustment. Careful monitoring by your healthcare team is essential throughout pregnancy and the postpartum period.

There are no restrictions on using Actrapid during breastfeeding. Insulin does not pass into breast milk in a way that could affect the nursing infant. However, your insulin dose and dietary plan may need to be adjusted during breastfeeding, as lactation can lower blood sugar levels.

Use in Children and Adolescents

Actrapid can be used in children and adolescents of all ages who require insulin therapy for diabetes. Dosing for children must be individually determined by a paediatric endocrinologist based on the child’s age, weight, blood sugar levels, physical activity, and growth stage. Parents and caregivers must be thoroughly trained in injection technique, blood sugar monitoring, and recognising and treating hypoglycemia. Insulin requirements may change during puberty and periods of rapid growth. The InnoLet pen's large dial may be especially helpful for caregivers assisting children with injections.

Driving and Operating Machinery

Your ability to concentrate and react may be impaired if you experience hypoglycemia (low blood sugar) or hyperglycemia (high blood sugar). This could put you and others at risk when driving or operating machinery. Ask your doctor whether it is safe for you to drive if you frequently experience low blood sugar episodes or if your warning symptoms of hypoglycemia are weakened or absent (hypoglycemia unawareness). Carry a source of fast-acting sugar in your vehicle at all times.

Sodium Content

Actrapid InnoLet contains less than 1 mmol sodium (23 mg) per dose, meaning it is essentially sodium-free. This is relevant for patients on a controlled sodium diet.

How Does Actrapid InnoLet Interact with Other Drugs?

Drug interactions with insulin are clinically significant because they can either increase or decrease blood sugar levels, sometimes unpredictably. Understanding these interactions is essential for safe diabetes management. Your doctor may need to adjust your Actrapid dose when you start, stop, or change the dose of another medication. Always inform your healthcare team about every medication you are taking.

Drugs That May Lower Blood Sugar (Increase Hypoglycemia Risk)

The following medications can enhance the blood sugar-lowering effect of Actrapid. When these drugs are used in combination with insulin, your risk of hypoglycemia increases and closer blood sugar monitoring is recommended:

Drugs That May Raise Blood Sugar (Decrease Insulin Effectiveness)

The following medications can counteract the effects of insulin and raise blood sugar levels. An increase in Actrapid dose may be required when starting these medications:

Drugs with Variable Effects on Blood Sugar

Octreotide and lanreotide, used for acromegaly (a rare hormonal disorder involving excess growth hormone production), may either raise or lower blood sugar levels depending on the individual circumstances. These medications require particularly careful blood sugar monitoring when used alongside insulin therapy.

Beta-blockers deserve special attention because, in addition to potentially lowering blood sugar, they can mask the typical warning signs of hypoglycemia — particularly the rapid heartbeat and trembling that normally alert patients to falling blood sugar levels. If you take a beta-blocker, you may need to rely on other symptoms (such as sweating or hunger) and more frequent blood glucose testing to detect low blood sugar.

Pioglitazone (an oral diabetes medication) used in combination with insulin has been associated with heart failure in some patients with long-standing type 2 diabetes and pre-existing heart disease or previous stroke. If you take pioglitazone with insulin, inform your doctor immediately if you experience signs of heart failure such as unusual shortness of breath, rapid weight gain, or localised swelling (oedema).

Alcohol

Alcohol can affect your insulin requirements unpredictably. It may initially raise blood sugar (particularly sweet or mixed drinks) but can cause a delayed and prolonged drop in blood sugar levels, especially when consumed without food. The liver prioritises metabolising alcohol over releasing glucose, impairing the body's ability to correct low blood sugar. If you choose to drink alcohol, do so in moderation, always eat food alongside it, monitor your blood sugar more frequently, and be aware that symptoms of hypoglycemia can be mistaken for intoxication by others.

What Is the Correct Dosage of Actrapid InnoLet?

The dosage of Actrapid is highly individualised and there is no single dose that works for everyone. Your doctor will determine your starting dose and make adjustments over time based on regular blood sugar monitoring, HbA1c levels, your diet, physical activity, body weight, other medications, and any concurrent illnesses. The overall aim of insulin therapy is to maintain blood sugar levels as close to normal as possible while minimising the risk of hypoglycemia.

Adults

Children

Elderly

Injection Technique with InnoLet

The Actrapid InnoLet pen is designed for ease of use. Follow these steps for each injection:

1. Check the insulin: Verify the label, expiry date, and that the solution is clear and colorless through the inspection window.
2. Attach a new needle: Use a NovoFine or NovoTwist needle. Remove both the outer and inner needle caps.
3. Prime the pen: Dial 2 units and press the injection button pointing upward until a drop appears at the needle tip. This removes air bubbles and confirms insulin flow.
4. Dial your dose: Turn the large dose selector to your prescribed number of units. Each click equals 1 unit. If you set the wrong dose, simply dial forward or backward to correct it.
5. Select the injection site: Rotate between the abdomen, thighs, buttocks, or upper arms. The abdominal wall generally provides the most consistent absorption.
6. Inject: Insert the needle at a 90-degree angle into a skin fold, press the injection button fully, and count slowly to 6 before withdrawing.
7. Remove the needle: Carefully remove and safely discard the needle. Replace the pen cap. Never store the pen with a needle attached.

Inject Actrapid approximately 30 minutes before a meal. You must eat a meal or snack containing carbohydrates within 30 minutes of injecting to prevent hypoglycemia. The preferred injection sites are the abdominal wall (fastest absorption), the thigh, the gluteal region (buttocks), or the deltoid region (upper arm). Always rotate within the same body region to reduce the risk of lipodystrophy.

Missed Dose

If you forget to inject Actrapid before a meal, check your blood sugar level. If it is still within your target range and you have not yet finished eating, you may inject a reduced dose during or shortly after the meal — but discuss this approach with your doctor in advance. Do not inject a double dose to make up for a missed injection. If you are unsure what to do, contact your healthcare provider. Frequent missed doses can lead to poor blood sugar control and should be discussed with your diabetes care team.

Overdose

What Are the Side Effects of Actrapid InnoLet?

Like all insulin products, Actrapid InnoLet can cause side effects, although not everybody experiences them. The risk and severity of side effects are closely related to insulin dose, injection technique, blood sugar monitoring, diet, and physical activity. Understanding potential side effects helps you recognise and respond to them promptly. If you experience any side effect that concerns you, contact your doctor or diabetes nurse for advice.

Understanding Hypoglycemia

Hypoglycemia is the most important and frequent adverse effect of insulin therapy. It occurs when blood sugar drops below approximately 3.9 mmol/L (70 mg/dL). The severity is classified by the type of response required:

• Level 1 (mild): Blood sugar below 3.9 mmol/L but above 3.0 mmol/L. You can recognise symptoms and treat yourself with fast-acting carbohydrate.
• Level 2 (moderate): Blood sugar below 3.0 mmol/L (54 mg/dL). Requires urgent treatment with carbohydrate and close monitoring.
• Level 3 (severe): Altered mental status or physical functioning requiring assistance from another person. May involve seizures or loss of consciousness. Requires emergency glucagon and/or medical care.

Common causes of hypoglycemia include injecting too much insulin, delaying or missing meals, exercising more vigorously than usual, drinking alcohol, and interactions with other medications. Always carry a source of fast-acting glucose (glucose tablets, fruit juice) and ensure that people around you know how to help in an emergency.

How Should You Store Actrapid InnoLet?

Correct storage of insulin is essential to maintain its potency and safety. Improperly stored insulin may lose its effectiveness without any visible change in appearance, potentially leading to dangerously high blood sugar levels. Follow these guidelines carefully:

Unopened Pens (Not Yet in Use)

• Store in a refrigerator at 2–8°C (36–46°F).
• Do not freeze. If the insulin has been frozen, discard it immediately — frozen insulin is permanently damaged and must not be used.
• Do not store directly next to the freezer compartment or freezer cooling elements.
• Keep the pen cap on to protect from light.
• Unopened pens can be stored until the expiry date printed on the label and outer carton.

In-Use Pens (Currently Being Used)

• Once in use, the pen can be carried with you and kept at room temperature (up to 30°C / 86°F).
• The in-use pen may be used for a maximum of 6 weeks, after which it must be discarded even if insulin remains.
• Do not refrigerate the pen once in use — cold insulin can be more painful to inject and may not absorb as consistently.
• Always replace the pen cap after each injection to protect from light.
• Never store the pen with a needle attached — this can cause insulin leakage, air entry, and inaccurate dosing.

Before Each Injection

Always check the insulin solution through the inspection window before each injection. Actrapid must always be clear and colorless. Do not use it if it appears cloudy, discolored, or contains visible particles. Also check the expiry date and ensure the pen has not been in use for longer than 6 weeks.

Disposal

Dispose of empty or expired Actrapid InnoLet pens according to your local regulations for medical waste. Do not dispose of pens in household waste without first removing the needle. Used needles should be placed in a sharps container. Never discard pens or needles where they could harm others, and keep all insulin products out of the reach and sight of children.

What Does Actrapid InnoLet Contain?

Active Ingredient

Each millilitre of Actrapid InnoLet solution contains 100 International Units (IU) of human insulin, equivalent to approximately 3.5 mg of anhydrous human insulin. The insulin is produced by recombinant DNA technology using Saccharomyces cerevisiae (baker's yeast) as the host organism. The resulting insulin is structurally identical to naturally occurring human insulin and is of high purity. Each pen contains 3 ml of solution, providing a total of 300 IU per pen.

Inactive Ingredients (Excipients)

The other ingredients in Actrapid InnoLet are:

• Zinc chloride: Stabilises the insulin hexamer structure during storage
• Glycerol: Acts as a tonicity agent to make the solution isotonic with body fluids
• Metacresol: Serves as a preservative to prevent microbial growth after the first use
• Sodium hydroxide and/or hydrochloric acid: Used for pH adjustment to ensure solution stability and comfort on injection
• Water for injections: The solvent that forms the basis of the injectable solution

Actrapid InnoLet does not contain any additional animal-derived ingredients. The product is latex-free. If you have known allergies to any of the listed excipients, particularly metacresol (a common preservative in insulin products), discuss alternative insulin formulations with your doctor.